Transcatheter Arterial Chemoembolization Combined with Sorafenib in Treatment of Intermediate or Advanced Hepatocellular Carcinoma of Chinese: A Meta Analysis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 GAOFei ,  HANBin , PANGZhi-gang , CHENWen-chao

Department of General Surgery, The Second Affiliated Hospital, Zhengzhou University, Zhengzhou 450014, Henan Province, China;

Corresponding author：

HANBin, Email: hanbin03@163.com

Keywords：

Transcatheter arterial chemoembolization; Sorafenib; Hepatocellular carcinoma; Meta analysis

DOI：

10.7507/1007-9424.20150250

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with sorafenib and TACE only treating the intermediate or advanced hepatocellular carcinoma (HCC) in Chinese people. Methods The PubMed, Embase, Cochrane Library, CBM, CNKI, VIP, and Wanfang Data for randomized controlled trials (RCT) on TACE combined with sorafenib (TACE combined with sorafenib group) and TACE (TACE alone group) from inception to December 2014 were searched. The literatures and data were screened and extracted. The meta analysis was performed using RevMan 5.1 software. Results Six RCTs involving 498 patients with HCC were included. The results of meta analysis showed that the objective response rate[OR=2.28, 95% CI (1.52-3.42), P < 0.000 1] and the disease control rate[OR=6.62, 95% CI (4.12-10.65), P < 0.000 01] were higher, the 1-year survival rate[OR=3.27, 95% CI (2.06-5.22), P < 0.000 01] and 2-year survival rate[OR=4.55, 95% CI (2.28-9.07), P < 0.000 1] were longer, the safety and tolerability of adverse reactions were better in the TACE combined with sorafenib group as compared with the TACE alone group. Conclusions In Chinese people, compared with TACE alone group, TACE combined with sorafenib group have higher objective response rate, disease control rate, 1-year survival rate, and 2-year survival rate. However, due to the lower quality of included literatures, these conclusions should be treated cautiously.

Citation： GAOFei, HANBin, PANGZhi-gang, CHENWen-chao. Transcatheter Arterial Chemoembolization Combined with Sorafenib in Treatment of Intermediate or Advanced Hepatocellular Carcinoma of Chinese: A Meta Analysis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(8): 962-966. doi: 10.7507/1007-9424.20150250 Copy

1.	杨家进, 吴建兵.原发性肝癌综合介入治疗进展.实用肝脏病杂志, 2015, 18(2):118-119.
2.	戴朝六, 贾昌俊.肝细胞癌规范诊治流程评价.中国实用外科杂志, 2014, 34(8):690-695.
3.	中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版).临床肿瘤学杂志, 2011, 16(10):929-946.
4.	Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma:the BCLC staging classification. Semin Liver Dis, 1998, 19(3):329-338.
5.	曾宪涛, 包翠萍, 曹世义, 等. Meta分析系列之三:随机对照试验的质量评价工具.中国循证心血管医学杂志, 2012, 4(3):183-185.
6.	Review Manager (RevMan)[Computer program]. Version 5.1. Copen-hagen:The Nordic Cochrane Centre, The Cochrane Collaboration, 2011 5.1. http://tech.cochrane.org/revman.
7.	姜海英, 谢晓东.索拉非尼联合TACE术治疗中晚期肝细胞癌30例临床观察.海南医学, 2010, 21(23):6-9.
8.	郭予武.肝动脉栓塞化疗术联合小分子靶向治疗晚期肝癌临床疗效观察.中国医学工程, 2012, 20(6):11-13.
9.	陈四明, 王豫山, 谢辉.索拉非尼联合TACE治疗老年原发性肝癌的临床观察.中国现代医学杂志, 2012, 22(25):71-73.
10.	曲捷.分子靶向药物-索拉非尼对晚期肝癌的疗效观察.长春:吉林大学, 2013.
11.	孙恒, 韩文杰. TACE联合索拉非尼对不能手术切除肝细胞肝癌的疗效分析.胃肠病学和肝病学杂志, 2014, 23(5):486-488.
12.	周仁贵, 周锡建, 李相勇, 等.索拉非尼联合化疗栓塞治疗晚期原发性肝癌的疗效分析.现代生物医学进展, 2014, 14(13):2494-2496.
13.	戴朝六, 赵阳.原发性肝癌的综合治疗.中国普外基础与临床杂志, 2014, 21(2):133-137.
14.	马坤, 梁定.中晚期肝癌治疗进展.国际肿瘤学杂志, 2012, 39(8):612-615.
15.	Fernández M, Semela D, Bruix J, et al. Angiogenesis in liver disease. J Hepatol, 2009, 50(3):604-620.
16.	Liapi E, Geschwind J. Chemoembolization for primary and metas-tatic liver cancer. Cancer J, 2010, 16(2):156-162.
17.	Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4):378-390.
18.	Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised, double-blind, placebo-controlled trial. Lancet Oncol, 2009, 10(1):25-34.
19.	De Lope CR, Tremosini S, Forner A, et al. Management of HCC. J Hepatol, 2012, 56:S75-S87.
20.	弋鹏圣, 张鸣, 徐明清.索拉菲尼治疗晚期肝癌的疗效与安全性评价.中国普外基础与临床杂志, 2014, 21(10):1268-1276.
21.	Cotter TG. Apoptosis and cancer:the genesis of a research field. Nat Rev Cancer, 2009, 9(7):501-507.
22.	陈逢生, 崔彦芝, 罗荣城, 等.索拉非尼联合顺铂对肝癌HepG2细胞的抑制作用.南方医科大学学报, 2008, 28(9):1684-1687.
23.	Richly H, Schultheis B, Adamietz IA, et al. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma:results from a phase I extension trial. Eur J Cancer, 2009, 45(4):579-587.
24.	Abou-Alfa GK, Schwartz L, Ricci S, et al. PhaseⅡstudy of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol, 2006, 24(26):4293-4300.
25.	Zhao Y, Wang WJ, Guan S, et al. Sorafenib combined with transar-terial chemoembolization for the treatment of advanced hepatoce-llular carcinoma:a large-scale multicenter study of 222 patients. Ann Oncol, 2013, 24(7):1786-1792.

1. 杨家进, 吴建兵.原发性肝癌综合介入治疗进展.实用肝脏病杂志, 2015, 18(2):118-119.
2. 戴朝六, 贾昌俊.肝细胞癌规范诊治流程评价.中国实用外科杂志, 2014, 34(8):690-695.
3. 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版).临床肿瘤学杂志, 2011, 16(10):929-946.
4. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma:the BCLC staging classification. Semin Liver Dis, 1998, 19(3):329-338.
5. 曾宪涛, 包翠萍, 曹世义, 等. Meta分析系列之三:随机对照试验的质量评价工具.中国循证心血管医学杂志, 2012, 4(3):183-185.
6. Review Manager (RevMan)[Computer program]. Version 5.1. Copen-hagen:The Nordic Cochrane Centre, The Cochrane Collaboration, 2011 5.1. http://tech.cochrane.org/revman.
7. 姜海英, 谢晓东.索拉非尼联合TACE术治疗中晚期肝细胞癌30例临床观察.海南医学, 2010, 21(23):6-9.
8. 郭予武.肝动脉栓塞化疗术联合小分子靶向治疗晚期肝癌临床疗效观察.中国医学工程, 2012, 20(6):11-13.
9. 陈四明, 王豫山, 谢辉.索拉非尼联合TACE治疗老年原发性肝癌的临床观察.中国现代医学杂志, 2012, 22(25):71-73.
10. 曲捷.分子靶向药物-索拉非尼对晚期肝癌的疗效观察.长春:吉林大学, 2013.
11. 孙恒, 韩文杰. TACE联合索拉非尼对不能手术切除肝细胞肝癌的疗效分析.胃肠病学和肝病学杂志, 2014, 23(5):486-488.
12. 周仁贵, 周锡建, 李相勇, 等.索拉非尼联合化疗栓塞治疗晚期原发性肝癌的疗效分析.现代生物医学进展, 2014, 14(13):2494-2496.
13. 戴朝六, 赵阳.原发性肝癌的综合治疗.中国普外基础与临床杂志, 2014, 21(2):133-137.
14. 马坤, 梁定.中晚期肝癌治疗进展.国际肿瘤学杂志, 2012, 39(8):612-615.
15. Fernández M, Semela D, Bruix J, et al. Angiogenesis in liver disease. J Hepatol, 2009, 50(3):604-620.
16. Liapi E, Geschwind J. Chemoembolization for primary and metas-tatic liver cancer. Cancer J, 2010, 16(2):156-162.
17. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4):378-390.
18. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phaseⅢrandomised, double-blind, placebo-controlled trial. Lancet Oncol, 2009, 10(1):25-34.
19. De Lope CR, Tremosini S, Forner A, et al. Management of HCC. J Hepatol, 2012, 56:S75-S87.
20. 弋鹏圣, 张鸣, 徐明清.索拉菲尼治疗晚期肝癌的疗效与安全性评价.中国普外基础与临床杂志, 2014, 21(10):1268-1276.
21. Cotter TG. Apoptosis and cancer:the genesis of a research field. Nat Rev Cancer, 2009, 9(7):501-507.
22. 陈逢生, 崔彦芝, 罗荣城, 等.索拉非尼联合顺铂对肝癌HepG2细胞的抑制作用.南方医科大学学报, 2008, 28(9):1684-1687.
23. Richly H, Schultheis B, Adamietz IA, et al. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma:results from a phase I extension trial. Eur J Cancer, 2009, 45(4):579-587.
24. Abou-Alfa GK, Schwartz L, Ricci S, et al. PhaseⅡstudy of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol, 2006, 24(26):4293-4300.
25. Zhao Y, Wang WJ, Guan S, et al. Sorafenib combined with transar-terial chemoembolization for the treatment of advanced hepatoce-llular carcinoma:a large-scale multicenter study of 222 patients. Ann Oncol, 2013, 24(7):1786-1792.

Previous Article
Strategies of Endovascular Repair for Complicated Stanford Type B Aortic Dissection
Next Article
Analysis of Related Risk Factors for Pancreatic Fistula Following Pancreaticoduodenec-tomy

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Transcatheter Arterial Chemoembolization Combined with Sorafenib in Treatment of Intermediate or Advanced Hepatocellular Carcinoma of Chinese: A Meta Analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content